Abstract: The present invention relates to a novel compound useful as a TRPV4 antagonist, specifically the compound 1-(((5S,7R)-3-(5-cyclopropylpyrazin-2-yl)-7-hydroxy-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl)methyl)-1H-benzo[d]imidazole-6-carbonitrile, pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compound.

Abstract: The present invention relates to a novel compound useful as a TRPV4 antagonist, specifically the compound 1-(((5S,7R)-3-(5-cyclopropylpyrazin-2-yl)-7-hydroxy-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl)methyl)-1H-benzo[d]imidazole-6-carbonitrile, pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compound.

Abstract: The present invention relates to spirocarbamate analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.

Abstract: The present invention relates to spirocarbamate compounds of Formula (I) in which R1, (R2)Y, R3, R4, X and A have the meanings given in the specification. The invention further provides pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and relates to their use of these compounds as TRPV4 antagonists in treating or preventing conditions associated with TRPV4 imbalance.

Abstract: The present invention relates to spirocarbamate compounds of Formula (I) in which R1, (R2)Y, R3, R4, X and A have the meanings given in the specification. The invention further provides pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and relates to their use of these compounds as TRPV4 antagonists in treating or preventing conditions associated with TRPV4 imbalance.

Abstract: The present invention relates to spirocarbamate analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.

Abstract: Disclosed are compounds having the formula: wherein R1 and R2 are as defined herein, and methods of making and using the same.

Abstract: Disclosed are aspartic protease inhibitors represented by the following Formula: wherein R1, R2, R3, R4, R5, R6, R7a, R7b and n are as defined herein, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods for treating an aspartic protease mediated disorder using the same.

Abstract: Disclosed is a process for the preparation of tetrahydropyran-di-amine represented by Structural Formula (I): wherein R1 is H or alkyl and E is H or an amine protecting group.

Abstract: Disclosed are compounds of Formula (I) wherein the R, R1, R2, R3, X, Y, A, Q, E, and G are defined herein. These compounds bind to aspartic proteases to inhibit their activity and are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also disclosed are methods of use of the compounds of Formula I for ameliorating or treating aspartic protease related disorders in a subject in need thereof.

Abstract: In the present invention method, the surface of articles made of acrylic polymers and methacrylic polymers are converted into thin biomimetic layers by using the process involving at least the following two steps:(a) The polymer surface is contacted, in the presence of water and for a predetermined reaction time necessary to form a continuous surface layer thinner than about 500 microns, with a solution containing one or more tetraalkylammonium hydroxides of the general formula:R.sub.1 R.sub.2 R.sub.3 R.sub.4 N.sup.+ OH.sup.-where R.sub.1, R.sub.2, R.sub.3, R.sub.4 are the alkyl substituents, in which the sum of the number of carbon atoms is equal to or larger than 8 but smaller than 45; and,(b) The article is removed from the aqueous reaction solution and excess of tetraalkylammonium hydroxide is removed from the polymer surface by washing the polymer with a liquid miscible with the tetraalkylammonium hydroxide.

Abstract: A hydrophilic coating composition used to impart increased lubricity and wettability to the surface of a hydrophobic substrate which is comprised of three essential components:1) Hydrogel-forming polymer component A2) Water-soluble polymer component B3) Common solvent C for the components A and BThe water-insoluble, hydrogel-forming component A consists of a segmented copolymer with long, hydrophilic terminal blocks and the essentially hydrophobic central section. The two polymer components A and B have a limited miscibility in the absence of a common solvent C. Therefore, their blend tends to separate spontaneously into two polymer phases. The phase separation takes place during the solvent evaporation or extraction. A gradient of hydrophilicity and swelling within the coating layer is thus spontaneously created achieving a good adhesion to the substrate and high surface hydrophilicity at the same time.